Intangible Assets

INAB does not show evidence of durable proprietary IP or branded demand power in the provided metrics, while peers with stronger clinical or regulatory assets typically sustain better pricing power.

Negative ROIC and ROCE indicate the company is not converting any intangible advantage into economic returns, unlike peers with approved products or defensible platforms that can monetize exclusivity.

The absence of disclosed long-run margin or return history in the supplied data weakens confidence that any patent, know-how, or regulatory asset is durable versus peers.

Without visible evidence of differentiated assets that protect retention or pricing, the moat appears more replicable than peer leaders in life sciences.

Switching Costs

The provided metrics do not indicate embedded customer workflows, recurring contracts, or integration depth, so switching costs appear materially lower than peers with platform or consumables lock-in.

Negative profitability suggests customers are not locked in by economic necessity, because a strong switching-cost moat usually supports steadier margins and returns than seen here.

The very weak capital efficiency implies the business is not retaining value through repeat usage or renewal behavior at a level comparable with more entrenched peers.

No evidence in the supplied data suggests that customers would face meaningful operational disruption by switching away from INAB.

Network Effects

The available metrics provide no sign of user-to-user, data, or ecosystem feedback loops, whereas peers with network effects typically show compounding retention and improving unit economics.

Negative ROIC and ROCE are inconsistent with a self-reinforcing adoption flywheel that would normally strengthen over time versus peers.

There is no evidence of scale-driven participation benefits, marketplace liquidity, or data accumulation that would make INAB more valuable as usage grows.

Compared with peer businesses that benefit from ecosystem gravity, INAB appears to lack a structural network-based moat.

Cost Advantage

The company’s negative ROIC and ROCE indicate it is not operating with a cost structure that converts into superior returns versus peers.

A strong cost advantage usually shows up as durable positive margins or capital efficiency, but the supplied metrics point in the opposite direction.

The negative cash conversion cycle alone does not establish a moat because it can reflect working-capital timing rather than a persistent peer-leading cost position.

Relative to peers with manufacturing scale, procurement leverage, or process efficiency, INAB does not show evidence of a durable cost edge.

Efficient Scale

The data do not indicate that INAB serves a market niche where one or a few firms can profitably dominate, which is the core requirement for efficient scale.

Negative returns suggest the company is not capturing the economics of a protected niche better than peers that operate in concentrated, capacity-constrained segments.

No evidence in the supplied metrics shows that market size, regulation, or infrastructure constraints are limiting entry in a way that would preserve pricing power.

Compared with peers that benefit from natural bottlenecks or regulated scarcity, INAB does not appear to have a durable efficient-scale advantage.

Overall Score

INAB shows no clear evidence of a durable economic moat in the supplied data, and its deeply negative ROIC/ROCE versus peers suggests weak pricing power, limited retention, and no visible structural advantage across the five moat drivers.